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Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify microRNAs in plasma for predicting
response to treatment and outcome. We have investigated microRNAs in plasma from ovarian cancer patients enrolled in a large
multicenter study (ICON7), investigating the effect of adding bevacizumab to standard chemotherapy in patients diagnosed with
epithelial ovarian cancer. Patients with different histology, grade, and FIGO stages were included (𝑛 = 207) in this study. Screening
of 754 unique microRNAs was performed in the discovery phase (𝑛 = 91) using TaqMan Low Density Arrays. The results
were validated using single assays and RT-qPCR. Low levels of miR-200b, miR-1274A (tRNALys5), and miR-141 were significantly
associated with better survival, confirmedwith log-rank test in the validation set.The level ofmiR-1274A (tRNALys5) correlated with
outcome was especially pronounced in the high-grade serous tumors. Interestingly, low level of miR-200c was associated with 5-
month prolongation of PFSwhen treatedwith bevacizumab compared to standard chemotherapy.We found prognostic significance
of miR-200b, miR-141, and miR-1274A (tRNALys5) in all histological types, where miR-1274A (tRNALys5)may be a specific marker
in high-grade serous tumors.The level of miR-200c may be predictive of effect of treatment with bevacizumab. However, this needs
further validation.
1. Introduction
Chemoresistance is an obstacle for effective treatment of
ovarian cancer. The majority of the ovarian cancer patients
are diagnosed at late stage with poor overall survival [1], due
to lack of symptoms in early stage. For patients with spread of
disease, the survival rate is low with standard chemotherapy
[2]. Despite development of new drugs, many patients do
not benefit from the treatment with these drugs. As of today,
patients responding to given treatment cannot be distin-
guished from those without response prior to administration.
Epithelial ovarian cancer can be divided into 5 histologi-
cal subtypes: high-grade serous, low-grade serous, mucinous,
clear cell, and endometrioid, of which high-grade serous car-
cinomas are the most common and most studied histological
type [2].
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During tumor development, the tumor vascularization is
essential in order to secure a persistent supply of blood, oxy-
gen, and nutrition to sustain the rapid rate of growth of tumor
cells. The tumor angiogenesis is controlled by a large number
of proangiogenic factors such as transforming growth factor
beta 1 (TGF-𝛽1), transforming growth factor alpha (TGF-𝛼),
and vascular endothelial growth factor (VEGF). The latter
has been identified as the key mediator and the VEGF family
consists of six members: VEGF-A, placenta growth factor
(PIGF), VEGF-B, VEGF-C, VEGF-D, and VEGF-E [3]. It is
suggested that, by inhibiting VEGF, the vascular permeability
can be reduced leading to a reduction in the tumor interstitial
pressure, hence improving the delivery of chemotherapeutic
drugs to the tumor [4].
Bevacizumab (anti-VEGF) is a recombinant humanized
monoclonal antibody which binds to all the isoforms of
VEGF-A [5]. Bevacizumab is approved by health authorities
(EMA and FDA) to be used in combination with chemother-
apy in a number of cancer types [6]. In ovarian cancer, beva-
cizumab is approved in combination with chemotherapy and
as monotherapy maintenance after chemotherapy. In a phase
3 randomized trial on ovarian cancer patients (ICON7), high-
risk patients showed prolonged progression free survival
(PFS) and overall survival (OS) when bevacizumab was
given together with standard chemotherapy followed by a
maintenance phase compared with standard chemotherapy
alone. This effect on survival was not seen among the non-
high-risk patients [7]. This underlines the importance of
discriminating between responders and nonresponders to
improve the outcome. In order to pinpoint patients benefit-
ting from the treatment, blood based predictive biomarkers
might be essential supplement for the clinicians when type of
treatment is chosen [8].
MicroRNAs are small nucleotides established as regula-
tors of mRNA translation and hence involved in both normal
and pathological processes in a cell. Dysregulation ofmicroR-
NAs has been reported in all stages and types of cancer, and
it has been demonstrated that microRNAs are involved in
mechanisms such as tumor growth, invasion, angiogenesis,
and immune evasion [9]. Recently, microRNAs have been
detected in biofluids such as blood, urine, saliva, and breast
milk [10]. In biofluids, these molecules are exceptionally
stable due to protection by proteins and extracellular vesicles
[11, 12]. This makes these molecules suitable as biomarkers
for cancer diagnosis, prognosis, and prediction of effect of
therapy. Circulating microRNAs as biomarkers have several
advantages compared with tissue-based markers. Blood is
easy to obtain; microRNA analyses are fast and cheap and
can be done repeatedly to monitor the disease. Previous
studies on tumor tissue have shown that microRNAs are
involved in chemoresistance [13]. In a study of paclitaxel
resistance in cultured ovarian cancer cells, overexpression of
17 microRNAs was detected in the resistant cells, and two
of these were also significantly associated with prognosis.
Further, downregulation of 4 microRNAs was found in the
paclitaxel sensitive cells [14].
The purpose of this study was to identify circulating
microRNAs able to identify ovarian cancer patients in high
risk for relapse. Further, the goal was to identify candidate
circulating microRNAs predictive of benefit from treatment
with bevacizumab so that toxicity and costs can be reduced
for patients with low chance of response.
2. Material and Methods
Ovarian cancer patients were enrolled in the ICON7 study, a
randomized, 2-arm, multicenter study designed to evaluate
the safety and efficacy of adding bevacizumab to standard
chemotherapy with carboplatin and paclitaxel, as previously
described [7].
Alongside the clinical study, patients were asked to
participate in a translational study. Research projects, utiliz-
ing ICON7 translational research samples, underwent peer
review and were approved by the Trial Management and
Steering Committees and the Ethics Committee in charge of
the trial.
Baseline blood samples (𝑛 = 207) were collected in
EDTA monovettes prior to administration of chemotherapy,
centrifuged (2000𝑔 for 10minutes at 20∘C) within 30minutes
of venepuncture, aliquoted, and stored at −80∘C according
to standard operating procedures. The plasma samples were
shipped to the central sample bank at the University of
Leeds, UK (R Banks), where they were stored anonymously
at −80∘C.
In order to identify microRNAs associated with progres-
sion free survival, samples in the upper and lower quartile of
progression free survival range were selected (𝑛 = 91) for the
discovery cohort (Table 1). The validation cohort consisted
of the remaining patients (𝑛 = 116). To test the predictive
potential of the microRNAs, the samples were also stratified
according to given treatment: standard chemotherapy and
standard chemotherapy plus bevacizumabwere called chemo
group and bevacizumab group, respectively. In this study,
grade 2 and 3 serous carcinomas are defined as high-grade.
2.1. MicroRNA Analysis. RNA was extracted from 500 𝜇L
plasma using miRCURY RNA isolation kit for biofluids
(cat# 300113, Exiqon, Denmark) as prescribed in the pro-
tocol. Then, 30 ng totRNA was reverse-transcribed using
megaplex RT primer pool (pools A and B, cat# 4444745,
Agilent Technologies, Santa Clara, CA) and TaqMan
MicroRNA reverse transcription kit (cat# 4366596, Agilent
Technologies, Santa Clara, CA). In order to increase the
sensitivity, preamplification of the cDNA was implemented
using megaplex preamp primer pool (pools A and B, cat#
4444748, Life Technologies) and TaqMan preamp master
mix (cat# 4391128, Agilent Technologies, Santa Clara, CA).
The samples were then mixed with TaqMan Universal PCR
Master Mix, NoAmpErase UNG, 2X, and applied to the
TaqMan Low Density Arrays (TLDA, cat# 4444913, Agilent
Technologies, Santa Clara, CA). The analysis was performed
at 7900HT Fast Thermocycler System (Agilent Technolo-
gies, Santa Clara, CA). The protocol from supplier (PN
4399721) was followed for all the procedures. The raw CT
data were exported to the ExpressionSuite software (v.1.0.3,
Applied Biosystem, Foster City, CA) for global normalization
and quality control. For the validation, the microRNAs of
interest were first reverse-transcribed and then quantified
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Table 1: Clinical information of all patients included in this study of microRNAs is given in the table. In the discovery set, samples collected
from patients with long PFS and short PFS are selected from the upper and lower quartile of PFS, respectively. Samples in the validation set
are recognized with less variation in survival time.
Discovery set Validation set
Bevacizumab
long PFS
Standard
chemotherapy
long PFS
Bevacizumab
short PFS
Standard
chemotherapy
short PFS
Bevacizumab Standardchemotherapy
Number of samples 𝑛 = 25 𝑛 = 26 𝑛 = 16 𝑛 = 24 𝑛 = 73 𝑛 = 43
Age (average) 56.4 57.1 56.6 59.8 53.8 58.1
Histology
Serous 16 17 11 14 49 30
Mucinous 0 0 0 2 0 0
Endometrioid 1 3 0 2 2 4
Clear cell 3 4 4 2 10 4
Mixed 4 2 1 1 10 3
Other 1 0 0 3 2 2
FIGO
IA/IB/IC 4 5 0 0 5 3
IIA/IIB/IIC 7 7 2 0 6 4
IIIA/IIIB/IIIC 13 14 10 18 51 32
IV 1 0 4 6 11 4
Grade
1 2 1 0 0 5 2
2 2 4 1 5 11 6
3 19 21 15 17 57 34
Unknown 2 0 0 2 1
PFS median (months) 28.8 29.4 8.1 7.2 18 12.9
Residual disease
Inoperable 0 0 1 3 1 2
Residual > 1 cm 3 4 6 12 24 17
Residual ≤ 1 cm 5 2 6 5 20 6
Residual 0 cm 17 20 3 3 28 18
using single assays and RT-qPCR. The procedures were per-
formed according to standard protocols.The procedures were
performed according to standard protocols. The primers,
reaction mix components, and temperature conditions used
for reverse transcription and qPCR are listed in Supplemen-
tary Table 1 in Supplementary Material available online at
https://doi.org/10.1155/2017/3098542. All samples were run
in triplicate. The comparative threshold (Ct) was used to
evaluate the relative detection level of each microRNA. Both
negative and positive controls were included. Pooled plasma
from women diagnosed with ovarian cancer was used as
positive control.
2.2. Normalization. The raw CT data were exported to
the ExpressionSuite software (v.1.0.3, Life Technologies) for
normalization and quality control. Threshold and baseline
were automatically calculated for each assay, and a global
normalizationwas performed as recommended for large scale
microRNA expression profiling [15]. The expression of each
microRNA was then mean centered using only expressed
microRNAs [16]. Normalized ΔCT data were used for cal-
culation of relative gene expression in fold change (2−ΔΔCt).
For validation of the selected microRNAs, the four most
uniformly expressed microRNAs (miR-220, miR-19b, sU6,
andmiR-320) from the TLDA cards were chosen as reference
genes for normalization. To obtainΔCT, the mean expression
level of the four microRNAs (CT ref ) was subtracted from the
meanCt level (CT target) of each sample.Due to low expression
of microRNAs in plasma, missing values were most likely the
results of too few RNA-copies. No detected measurements
were replaced with zero in linear scale. For the logarithmic
scale, the lowest expressed value for eachmicroRNA replaced
the missing values [17]. MicroRNAs detected in less than
30% of the samples were removed. Preamplification was not
utilized in the validation and Ct values of <40 indicated the
presence of microRNA.
2.3. Statistics. Significance analysis of microarrays (SAM)
was performed in J-express to identify microRNAs with
differential abundance in groups of interest [18]. Kaplan-
Meier survival analysis, log-rank test, and multivariate Cox
regression analysis were performed in SPSS (IBM SPSS
Statistics, Version 21.0. Armonk, NY: IBM Corp). In the Cox
multivariate analysis histology, grade, FIGO stage, residual
disease, type of treatment, and age were included. PFS was
calculated from the date of randomization to the date of dis-
ease progression or death, whichever occurred first. Patients
who were still alive without progression were censored at the
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Table 2:The levels of 6 identifiedmicroRNAs were investigated for association with survival irrespective of treatment group, in the discovery
set and in the validation set. False discovery rate (FDR) is shown in the discovery set, and the 𝑝 values from Student’s 𝑡-test are applied in
the validation set. The prognostic value of the six microRNAs was also tested in all the histology types combined, in addition to high-grade
serous samples separately. NA = not applicable and NS = not significant.
Discovery set Validation set
Histology All histologies combined
(𝑛 = 91)
High-grade
serous (𝑛 = 58)
All histologies combined
(𝑛 = 116)
High-grade
serous (𝑛 = 71)
MicroRNA SAM analysis Log-rank test Log-rank test
Student’s
𝑡-test Log-rank test Log-rank test
FDR 𝑝 value 𝑝 value 𝑝 value 𝑝 value 𝑝 value
miR-1274A <0.001 0.002 0.031 0.61 0.48 0.012
miR-141 <0.001 0.011 0.111 0.012 0.013 0.099
miR-200b <0.001 0.024 0.01 0.014 0.003 0.288
miR-200c <0.001 0.001 0.007 0.092 0.305 0.17
miR-520d-3p <0.001 NS NA 0.343 NA NA
miR-520c-3p <0.001 NS NA 0.742 NA NA
date of their last assessment. Student’s 𝑡-test was appliedwhen
applicable. Statistical significance was considered with 𝑝 <
0.05 or for multiple testing, false discovery rate (FDR) < 0.05.
3. Results
3.1. Study Design and Patient Characteristics. Totally, we used
plasma samples collected from 207 patients with epithelial
ovarian cancer. For patients selected for the discovery set, the
group with long PFS had a median survival of 29 months and
the groupwith short PFS had amedian PFS of 7.8months.The
median PFS for patients in the validation set was 17 months.
The patient characteristics for the two sets are given in Table 1.
Treatmentwith bevacizumabhadno prognostic impact in the
discovery set but was of independent prognostic significance
for PFS in the validation set (𝑝 < 0.001, HR = 0.37, CI 95% =
0.23–0.60).
3.2. Selection of miRNA Associated with Prognosis. In the
discovery set, 754 unique microRNAs were profiled.We were
able to measure 403 different microRNAs in more than 30%
of the samples, whereas 104microRNAs were detectable in all
the samples.
In the discovery set, we found 6microRNAs (miR-1274A,
miR-141, miR-200b, miR-200c, miR-520c-5p, and miR-520d-
5p) with significantly higher abundance in patients reported
with short PFS compared with those with long PFS (SAM
analysis, FDR < 0.001, Table 2). The log-rank test revealed 4
microRNAs (miR-1274A, miR-141, miR-200b, andmiR-200c)
significantly associatedwith survival. In the validation set, the
log-rank test confirmed the prognostic association for miR-
141 and miR-200b (Table 2 and Figure 1). In the multivariate
Cox regression test, miR-200b obtained significance (𝑝 =
0.006, HR = 0.79, CI 95% = 0.68–0.94) and miR-1274A was
of borderline significance (𝑝 = 0.085, HR = 0.85, CI 95% =
0.70–1.02), while miR-141 did not obtain significance (𝑝 =
0.153, HR = 0.91, CI 95% = 0.81–1.03). Type of treatment,
FIGO stage, and residual disease all obtained significance
(Table 3).
Since high-grade serous carcinoma is the largest group,
the same statistical analyses were applied to this group. In
the high-grade serous carcinomas, low levels of miR-1274A
were significantly associated with prolonged survival in the
log-rank test both in the discovery set (𝑝 = 0.031) and
in the validation set (𝑝 = 0.012). The same tendency
was seen for miR-141 and miR-200c, although this was not
significant in the validation set (Table 2). In the multivariate
Cox regression analysis on the validation set, miR-1274A
obtained independent significance (𝑝 = 0.041, HR = 0.78,
CI 95% = 0.62–0.99), while miR-141 and miR-200b did not
obtain independent significance (𝑝 = 0.69 and 𝑝 = 0.15,
resp.). The remaining histological groups were too small for
group specific analyses. The level of miR-520d-3p and miR-
520c-3p was also analysed in the validation set, but, due to
very low abundance andmany cases with no detected signals,
these microRNAs were not included in further analyses.
3.3. Evaluation of MicroRNA as a Possible Predictive Factor.
To evaluate the predictive potential of the microRNAs, we
checked if there was significantly different time to progres-
sion between the two treatment groups related to the level
of the microRNAs in plasma. We stratified the microRNAs
based on high and low abundance with the median as cutoff.
In the discovery group, we did not see any difference in
PFS between the two treatments groups related to abundance
of the microRNAs. In the validation set, miR-200c were
associated with significantly better survival in the log-rank
test when treated with bevacizumab, compared to standard
chemotherapy with a median PFS of 19.5 months and 14.5
months, respectively (𝑝 = 0.006, Figure 2). This was
confirmed by multivariate Cox regression (𝑝 < 0.0001, HR =
4.33, CI 95% = 1.96–9.58). No significant differences between
treatments were seen with high levels of miR-200c.
Low levels of miR-200b andmiR-141 were associated with
significantly better PFS in the log-rank test when treated with
bevacizumab compared to standard chemotherapy, but this
was not confirmed when adjusting for explanatory variables
in multivariate Cox regression analysis.
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Figure 1: The prognostic potential of miR-200b and miR-141 is displayed using Kaplan-Meier survival plot and log-rank test was performed
on data obtained from the discovery set and the validation set. High abundance means abundance above median and low abundance means
under median. PFS = progression free survival in months. Cum survival = cumulative survival.
4. Discussion
We identified 4 microRNAs (miR-200b, mir-200c, miR-
1274A, and miR-141) significantly associated with survival in
the discovery set. The prognostic significance of miR-200b
and miR-141 was confirmed in the validation set using the
log-rank test.When adjusting for other explanatory variables,
level of miR-200b was significant, and miR-1274A and miR-
141 were of borderline significance. When evaluating the
high-grade serous group alone, miR-1274A was found of
independent prognostic significance. In these evaluations,
the small number of patients should be taken into account.
We believe that biomarkersmeasured in blood are of great
value since it is less invasive, easy to obtain, cost-effective,
and fast. On the other hand, there are also challenges in
working with microRNAs in blood. The level of circulating
microRNAs can be very low, and blood contains several
components which may influence the analysis. Therefore,
when working with microRNAs, choice of method is crucial.
In this study, quantitative real-time PCR, known as a very
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Table 3: Cox regression analysis shows the variables significantly associated with prognosis. Variables not significant are left out of the final
model except from miR-1274A and miR-141. In the full model, the variables including age, FIGO stage, grade, residual disease, and type of
treatment were included in addition to the 4 microRNAs.
Variable 𝑝 value HR 95% CI for HR
mir 1274B 0.085 0.846 0.70–1.02
miR 200b 0.006 0.798 0.68–0.94
miR-141 0.153 0.914 0.81–1.03
FIGO stage
Stage I (reference) 0.08
Stage II 0.911 1.073 0.31–3.68
Stage III 0.352 1.564 0.61–4.01
stage IV 0.036 3.368 1.08–10.49
Residual disease
No residual disease (reference) <0.001
Residual 0-1 cm 0.853 0.863 0.18–4.13
Residual > 1 cm <0.001 3.005 1.70–5.31
Inoperable <0.001 3.259 1.76–6.04
Treated with bevacizumab versus chemotherapy <0.001 0.373 0.23–0.60
p = 0.006 p = 0.350
Low abundance of miR-200c High abundance of miR-200c
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Figure 2: The Kaplan-Meier plot shows that low levels of miR-200c are associated with significantly better survival when bevacizumab is
added to standard chemotherapy, compared to standard chemotherapy alone. Standard chemotherapy is carboplatin and paclitaxel. PFS =
progression free survival in months. Cum survival = cumulative survival. High levels of miR-200c were not predictive of therapy.
robust, accurate, and sensitive method, was chosen [19].
To date, several microRNA candidates have been identified
as diagnostic, prognostic, or predictive biomarkers [20] in
ovarian cancer patients. However, most of these studies have
been performed in ovarian tissue or cell lines and with
contradictory results. Interestingly, Chen et al. investigated
8 published microRNA expression studies in ovarian cancer
and revealed that four differentially expressed microRNAs
(miR-200a, miR-141, miR-200b, and miR-200c), all members
of the miR-200 family, were consistently upregulated in
tumor samples in four or more of the studies [21]. Moreover,
the level of miR-141, miR-200b, and miR-200c derived from
exosomes in blood has been reported to correlate with the
level in ovarian tumor cells [22].This is in linewith our results
where the level of miR-141 and miR-200b was elevated in
ovarian cancer patients with poor survival compared to those
with longer PFS in both the discovery and the validation set.
The prognostic potential of miR-200 family has been eluci-
dated and validated in numerous of cancer diseases including
ovarian cancer, colorectal cancer, and lung cancer [23–25].
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In a recent study, miR-1274A was found elevated in
plasma from patients diagnosed with serous epithelial ovar-
ian cancer [26]. A large number of microRNAs have recently
been refined in themiRBase and only 1/3 of the first annotated
microRNAs seem to be real microRNAs [27]. Recent data
suggests that miR-1274A probably is a fragment from the 3󸀠
end of Lys tRNA (tRNALys5) [28]. Interestingly, tRNA frag-
ments have proven to havemany different function, including
a regulatory capacity [29]. Moreover, miR-1274 (tRNALys5)
is found with high amounts in extracellular vesicles derived
from human breast cancer cells [30].
When this study was initiated, plasma from individuals
with very different time to progression was selected for
the discovery set and the remaining samples were later
supplied for validation. The remaining samples came from
individuals with minor differences in time to progression.
Another difference between the two data sets was the use of
preamplification. This was implemented in order to increase
the sensitivity of microRNAs in the discovery phase but
was not done in the validation set. In the discovery set,
two of the identified microRNAs (miR-520c-3p and 520d-
3p) were detected at very low levels in only 38% and 67%
of the samples, respectively. These were excluded for further
analysis.
In the discovery set, miR-200c was the microRNA most
significantly associated with survival. However, this was not
confirmed in the validation set. This might indicate that
the prognostic potential of this microRNA is detected only
in samples with high variance in survival. The possible
prognostic role of miR-200c should be further explored in
an independent study. In a study of microRNAs in serum of
epithelial ovarian cancer, miR-200b and miR-200c showed
high levels in serum compared with normal controls. In
addition, the level of miR-200c was associated with pro-
gression of the disease [23]. Despite two very different data
sets, we did identify microRNAs with prognostic potential.
Bearing the differences in the two data sets and the small
numbers in mind, the prognostic value of miR-1274A seems
robust, at least in high-grade serous ovarian carcinoma,
and a prognostic value of miR-141and miR-200b seems
likely.
To further test if any of the microRNAs were predictive of
therapy response, we assumed that either low or high levels
of the microRNAs would show different time to progression
between the treatment groups. In the discovery set, no
differences were seen. However, in the validation set, low
level of miR-200c was significantly associated with better sur-
vival when treated with bevacizumab compared to standard
chemotherapy. This was still significant after correcting for
explanatory variables. Treatment with bevacizumab had no
prognostic impact in the discovery set, which may explain
that no microRNA had predictive value in this set. Our
findings may indicate that low level of miR-200c in plasma
is a predictive marker for pinpointing the patients benefitting
from adding bevacizumab to the treatment. However, vali-
dation of the predictive potential of miR-200c is necessary.
Interestingly, members of the miR-200 family have been
identified as pivotal in several malignant processes, such as
epithelial to mesenchymal transition (EMT), angiogenesis,
and apoptosis [31–33]. In a study of colorectal cell lines,
miR-200c was involved in regulation of migration and
tube formation during angiogenesis [32]. This may explain
the relation between miR-200c in plasma and response to
the antiangiogenesis drug, bevacizumab, we found in our
study.
Studies of microRNAs predictive of treatment have
mostly been performed in ovarian tissue, such as low levels
of miR-378 reported to be associated with better response to
bevacizumab [34] and a signature of 3microRNAs predicting
chemoresistance in serous epithelial ovarian carcinomas
[13]. Recently, in matched biopsies from ovarian cancer
patients, four microRNAs were associated with prognosis
and response to platinum-based neoadjuvant chemotherapy
response [35]. Few studies have so far identified circulating
microRNAs in this context. However, in a study of colorectal
cancer, circulating levels of miR-126 have been found to pre-
dict treatment response to chemotherapy and bevacizumab
[36].
A shift in treatment strategies for ovarian cancer patients
is evolving, from treating the majority of patients simi-
larly to a more personalized treatment based on molecular
aberrations [37]. The response to a given treatment can be
difficult to predict upfront and the most efficient therapy
might not be given. Despite accumulating data of the biology
involved in chemosensitivity and chemoresistance, markers
for pinpointing the patients who will benefit from a given
therapy are lacking [38]. Robust prognostic markers in blood
would help clinicians to identify patients at higher risk of
relapse and tailor the treatment regimen or spare the patients
at low risk the side effects of treatment [39].
5. Conclusion
We identified miR-200b as a robust prognostic marker able
to detect ovarian cancer patients with high risk of relapse
independent of stage, histology, and residual tumor after
surgery. We found miR-141 to be a potential prognostic
marker. In addition, miR-1274A was a prognostic marker
in patients with high-grade serous ovarian cancer. We will
also propose miR-200c as a potential circulating biomarker
for prediction of better outcome after treatment with beva-
cizumab in combination with standard chemotherapy. These
results need further validation for clinical utility. This is the
first study to identify plasma microRNAs potentially able to
predict response to bevacizumab.
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